Altimmune (ALT) Total Liabilities (2010 - 2026)
Altimmune (ALT) posted quarterly Total Liabilities of $51.6 million for Q1 2026, up 241.98% year-over-year from $15.1 million in Q1 2025, and down 6.17% quarter-over-quarter from $55.0 million in Q4 2025.
Altimmune (ALT) Total Liabilities (2010 - 2026) Analysis & Trends
Altimmune (ALT) has reported Total Liabilities for 17 consecutive years, with $51.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 241.98% year-over-year to $51.6 million; the TTM figure through Mar 2026 stood at $51.6 million (up 241.98% YoY), while the FY2025 annual figure was $55.0 million, up 248.38% from the prior year.
- Total Liabilities eased to $51.6 million in Q1 2026 per ALT's latest filing, from $55.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $55.0 million in Q4 2025 and bottomed at $14.5 million in Q3 2024.
- Historically, Total Liabilities has averaged $23.3 million across 5 years, with a median of $19.4 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities declined 26.75% — and 2025, when it soared 248.38%.
- Altimmune's Total Liabilities stood at $21.6 million in 2022, then declined by 23.55% to $16.5 million in 2023, then retreated by 4.49% to $15.8 million in 2024, then jumped by 248.38% to $55.0 million in 2025, then decreased by 6.17% to $51.6 million in 2026.
- Business Quant data shows ALT's Total Liabilities at $51.6 million in Q1 2026, $55.0 million in Q4 2025, and $32.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Altimmune | 571.75 Mn | 571.75 Mn | - | 53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.00 Mn |
| Mar 31, 2026 | 51.64 Mn |
| Dec 31, 2025 | 55.04 Mn |
| Sep 30, 2025 | 32.85 Mn |
| Jun 30, 2025 | 28.98 Mn |
| Mar 31, 2025 | 15.10 Mn |
| Dec 31, 2024 | 15.80 Mn |
| Sep 30, 2024 | 14.49 Mn |
| Jun 30, 2024 | 20.82 Mn |
| Mar 31, 2024 | 15.42 Mn |
| Dec 31, 2023 | 16.54 Mn |
| Sep 30, 2023 | 16.18 Mn |
| Jun 30, 2023 | 15.60 Mn |
| Mar 31, 2023 | 19.35 Mn |
| Dec 31, 2022 | 21.64 Mn |
| Sep 30, 2022 | 20.25 Mn |
| Jun 30, 2022 | 15.37 Mn |
| Mar 31, 2022 | 20.79 Mn |
| Dec 31, 2021 | 19.73 Mn |
| Sep 30, 2021 | 27.64 Mn |